<DOC>
	<DOC>NCT00390910</DOC>
	<brief_summary>This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) BiologicalsÂ´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life. This protocol posting deals with objectives &amp; outcome measures of the primary study. The objectives &amp; outcome measures of the Booster study are presented in a separate protocol posting (NCT number = 00609492)</brief_summary>
	<brief_title>Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants</brief_title>
	<detailed_description>The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol A male or female between, and including, 816 weeks (56118 days) of age at the time of the first vaccination. Written informed consent obtained from the parent or guardian of the subject. Born after a gestation period of &gt;27 weeks (at least 189 days). If full term born, healthy subjects as established by medical history and clinical examination before entering into the study If premature, medically stable condition (not requiring significant medical support or ongoing management for debilitating disease and having demonstrated a clinical course of sustained recovery). Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs from birth to the first vaccine dose. Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting from one month before the first dose of vaccines and up to Visit 6. Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Neisseria meningitidis and/or Streptococcus pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, Neisseria meningitidis. History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. History of any neurologic disorders or seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past). Acute disease at the time of enrolment. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination A family history of congenital or hereditary immunodeficiency. Major congenital defects or serious chronic illness. Administration of immunoglobulins, with the exception of monoclonal antibodies against RSV, and/or any blood products within one month preceding the first dose of study vaccines or planned administration during the active phase of the study.</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Preterm</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>